ロード中...
The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer. Bevacizumab has demonstrated a gain in progression-free survival and a trend towards an overall survival benefit in v...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing AG
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3661078/ https://ncbi.nlm.nih.gov/pubmed/23710429 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2193-1801-2-202 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|